secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001558370-24-001304
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune regains Nasdaq minimum bid price compliance; ADSs to remain listed
------------------------------------------------------------------------------

- Received Nasdaq letter on Feb 16, 2024 confirming compliance with Listing Rule 5450(a)(1).
- Previously notified of non-compliance on Aug 31, 2023; ADSs closed below $1.00 for 30 consecutive days.
- Closing bid price exceeded $1.00 for ten consecutive trading days through Feb 15, 2024.
- Company now in full compliance with all Nasdaq listing standards; matter closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024001304/0001558370-24-001304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000155837024001304/adap-20240216x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer